JP2004507559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507559A5 JP2004507559A5 JP2002523958A JP2002523958A JP2004507559A5 JP 2004507559 A5 JP2004507559 A5 JP 2004507559A5 JP 2002523958 A JP2002523958 A JP 2002523958A JP 2002523958 A JP2002523958 A JP 2002523958A JP 2004507559 A5 JP2004507559 A5 JP 2004507559A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- atcc accession
- number pta
- accession number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 71
- 102000044591 ErbB-4 Receptor Human genes 0.000 description 16
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 16
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 208000031481 Pathologic Constriction Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- 208000037804 stenosis Diseases 0.000 description 10
- 230000036262 stenosis Effects 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 9
- 230000005012 migration Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 206010057469 Vascular stenosis Diseases 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22967900P | 2000-09-01 | 2000-09-01 | |
| US26551601P | 2001-01-31 | 2001-01-31 | |
| US09/940,101 US20020119148A1 (en) | 2000-09-01 | 2001-08-27 | ErbB4 antagonists |
| PCT/US2001/026984 WO2002018444A2 (en) | 2000-09-01 | 2001-08-29 | Erbb4 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507559A JP2004507559A (ja) | 2004-03-11 |
| JP2004507559A5 true JP2004507559A5 (enExample) | 2008-10-09 |
Family
ID=27397993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002523958A Pending JP2004507559A (ja) | 2000-09-01 | 2001-08-29 | ＥｒｂＢ４アンタゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20020119148A1 (enExample) |
| EP (1) | EP1351744B1 (enExample) |
| JP (1) | JP2004507559A (enExample) |
| AT (1) | ATE374642T1 (enExample) |
| AU (2) | AU8691801A (enExample) |
| CA (1) | CA2420062C (enExample) |
| DE (1) | DE60130797T2 (enExample) |
| DK (1) | DK1351744T3 (enExample) |
| ES (1) | ES2295202T3 (enExample) |
| IL (2) | IL154495A0 (enExample) |
| WO (1) | WO2002018444A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
| WO2002098445A1 (fr) * | 2001-05-30 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preparation de proteines |
| AU2003237367A1 (en) * | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
| DK2263691T3 (da) | 2002-07-15 | 2012-10-22 | Hoffmann La Roche | Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4) |
| US8505468B2 (en) * | 2002-11-19 | 2013-08-13 | Sharp Kabushiki Kaisha | Substrate accommodating tray |
| JP4527388B2 (ja) * | 2003-12-11 | 2010-08-18 | 東洋鋼鈑株式会社 | ポリペプチドとレセプターとの相互作用を検出する方法、該検出する方法を用いてリガンドまたはリガンド変異体をスクリーニングする方法および該検出する方法を用いる診断方法 |
| CN114053429A (zh) | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP1856158A4 (en) * | 2005-03-07 | 2010-07-28 | Targeted Molecular Diagnostics | TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS OF MAKING SAME AND USE THEREOF IN TREATING DISEASE |
| CA2678181C (en) * | 2007-02-16 | 2016-12-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| WO2009121004A2 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
| BRPI0917871A2 (pt) * | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| AU2009324939B2 (en) | 2008-11-25 | 2015-07-09 | Genentech, Inc. | Isoform specific anti-HER4 antibodies |
| MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| BR112012012983A2 (pt) | 2009-12-04 | 2020-09-15 | Genentech Inc | método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições |
| SG10201913463QA (en) | 2010-02-08 | 2020-03-30 | Regeneron Pharma | Common light chain mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| WO2011107100A1 (en) | 2010-03-03 | 2011-09-09 | Aarhus Universitet | Methods and compositions for regulation of herv4 |
| AU2011224186C1 (en) | 2010-03-11 | 2015-04-02 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| WO2012099566A1 (en) | 2010-11-17 | 2012-07-26 | Sea Lane Biotechnologies, Llc | Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody |
| HUE068728T2 (hu) | 2011-08-05 | 2025-01-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| CN104755499B (zh) * | 2012-11-08 | 2020-10-02 | 霍夫曼-拉罗奇有限公司 | 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白 |
| MX2015005757A (es) | 2012-11-08 | 2015-11-18 | Hoffmann La Roche | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3. |
| CA2902505A1 (en) | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| SG10201808225TA (en) | 2014-03-21 | 2018-10-30 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
| FR3020063A1 (fr) * | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | Anticorps humain anti-her4 |
| US9783611B2 (en) | 2014-05-14 | 2017-10-10 | Hoffman-La Roche Inc. | Anti-HER3 antibodies binding to the beta-hairpin of HER3 |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| EP4072682A1 (en) * | 2019-12-09 | 2022-10-19 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Antibodies having specificity to her4 and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0444961A1 (en) | 1990-03-02 | 1991-09-04 | Bristol-Myers Squibb Company | Her3: A novel EGF receptor homolog |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| MD1861G2 (ro) | 1994-11-14 | 2002-09-30 | Уорнер-Ламберт Кампэни | Derivaţi ai 6-arilpirido[2,3-d]pirimidinelor şi naftiridinelor, compoziţie farmaceutică pe baza lor, metode de tratament şi de inhibare a proliferării şi migraţiei celulei receptorului tirozinkinazei |
| US5770567A (en) * | 1994-11-14 | 1998-06-23 | Genentech, Inc. | Sensory and motor neuron derived factor (SMDF) |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| ATE290595T1 (de) * | 1996-07-12 | 2005-03-15 | Genentech Inc | Gamma-heregulin |
| CA2258721C (en) * | 1996-07-12 | 2014-09-09 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| ES2335365T3 (es) * | 1996-11-27 | 2010-03-25 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina a. |
| US6121415A (en) | 1997-07-09 | 2000-09-19 | Genentech, Inc. | ErbB4 receptor-specific neuregolin related ligands and uses therefor |
| US6994856B1 (en) * | 1997-07-24 | 2006-02-07 | Genentech, Inc. | ErbB4 receptor-specific neuregulin related ligands and uses therefor |
| WO1999019488A1 (en) | 1997-10-15 | 1999-04-22 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
| HUP0104211A3 (en) | 1998-11-19 | 2003-01-28 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it |
| EP1292619B1 (en) * | 2000-06-06 | 2008-02-06 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
-
2001
- 2001-08-27 US US09/940,101 patent/US20020119148A1/en not_active Abandoned
- 2001-08-29 AT AT01966399T patent/ATE374642T1/de active
- 2001-08-29 CA CA2420062A patent/CA2420062C/en not_active Expired - Fee Related
- 2001-08-29 EP EP01966399A patent/EP1351744B1/en not_active Expired - Lifetime
- 2001-08-29 AU AU8691801A patent/AU8691801A/xx active Pending
- 2001-08-29 JP JP2002523958A patent/JP2004507559A/ja active Pending
- 2001-08-29 WO PCT/US2001/026984 patent/WO2002018444A2/en not_active Ceased
- 2001-08-29 US US10/362,380 patent/US7332579B2/en not_active Expired - Fee Related
- 2001-08-29 IL IL15449501A patent/IL154495A0/xx unknown
- 2001-08-29 DE DE60130797T patent/DE60130797T2/de not_active Expired - Lifetime
- 2001-08-29 ES ES01966399T patent/ES2295202T3/es not_active Expired - Lifetime
- 2001-08-29 DK DK01966399T patent/DK1351744T3/da active
- 2001-08-29 AU AU2001286918A patent/AU2001286918B2/en not_active Ceased
-
2003
- 2003-02-17 IL IL154495A patent/IL154495A/en not_active IP Right Cessation
-
2005
- 2005-10-11 US US11/248,122 patent/US20060093603A1/en not_active Abandoned
-
2006
- 2006-10-13 US US11/581,221 patent/US20070092513A1/en not_active Abandoned
-
2008
- 2008-06-24 US US12/215,200 patent/US7704498B2/en not_active Expired - Fee Related
-
2010
- 2010-04-02 US US12/753,792 patent/US20100190964A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004507559A5 (enExample) | ||
| CN102209730B (zh) | 抗cxcr4抗体及其用于治疗癌症的用途 | |
| RU2640252C2 (ru) | Антитела против фактора роста нервов и способы их получения и применения | |
| CN109952317A (zh) | 使用pd-1结合蛋白治疗免疫病症的方法 | |
| JP2012515746A (ja) | 抗ｃｄ１６０モノクローナル抗体及びその使用 | |
| CN112867507A (zh) | 新型抗sirpa抗体 | |
| MXPA06010929A (es) | Anticuerpos anti-miostatina. | |
| JP2013529059A5 (enExample) | ||
| CN109689687A (zh) | 抗met抗体及其应用 | |
| EP4296357A1 (en) | Novel anti-pad4 antibody | |
| CN116323666A (zh) | Fgfr3抗体和使用方法 | |
| AU2022419233A1 (en) | Treatment paradigm for an anti-cd19 antibody therapy | |
| CN116514970A (zh) | 靶向rankl的治疗性抗体 | |
| JPWO2020180819A5 (enExample) | ||
| US20230399390A1 (en) | Novel anti-nogo-a antibodies | |
| CN118063609A (zh) | 抗cd39抗体及其应用 | |
| CN120712286A (zh) | 抗体、抗原结合片段和使用方法 | |
| US20230391863A1 (en) | Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof | |
| US20230391892A1 (en) | Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof | |
| WO2025103260A1 (zh) | Gdf15中和抗体及其用途 | |
| CN116284394A (zh) | 分离的抗原结合蛋白及其应用 | |
| HK40086174A (zh) | 分离的抗原结合蛋白及其应用 | |
| CN117980342A (zh) | 抗her2抗体及其使用方法 | |
| CN118745231A (zh) | 抗ror1和cd3的双特异性抗体及其应用 | |
| HK40114319A (zh) | 靶向usag-1分子的用於牙齿再生治疗的中和抗体 |